Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
If you are unable to participate during the live event, a replay of thewebcast will be available for a limited time at http://www.isispharm.com.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop noveldrugs for its product pipeline and for its partners. The Company hassuccessfully commercialized the world's first antisense drug and has 19 drugsin development. Isis' drug development programs are focused on treatingcardiovascular and metabolic diseases. Isis' partners are developingantisense drugs invented by Isis to treat a wide variety of diseases. IbisBiosciences, Inc., Isis' majority-owned subsidiary, is developing andcommercializing the Ibis T5000(TM) Biosensor System, a revolutionary system toidentify infectious organisms. Isis is a joint owner of Regulus TherapeuticsLLC, a joint venture focused on the discovery, development andcommercialization of microRNA therapeutics. As an innovator in RNA-based drugdiscovery and development, Isis is the owner or exclusive licensee of over1,500 issued patents worldwide. Additional information about Isis isavailable at http://www.isispharm.com.What: Abbott's exercise of its option to purchase Ibis Biosciences, a subsidiary of Isis. Total acquisition price will be $215 million. When: Wednesday, December 17, 2008 at 8:30 a.m. ET / 5:30 a.m. PT Where: http://www.isispharm.com How: Live on the Internet. Simply log onto our Web site listed above. Contacts: Kristina Lemonidis Associate Director, Corporate Development (760) 603-2490 Amy Blackley, Ph.D. Manager, Corporate Communications (760) 603-2772
SOURCE Isis Pharmaceuticals, Inc.
You May Also Like